Bet proteins - OmicsDI

Show results for

Unknown (871)
Genomics (487)
Transcriptomics (347)
Proteomics (66)
Other (22)
Models (4)
Metabolomics (4)
Methylation profiling (3)
Clinical (2)

Organisms

Homo sapiens (292)
Mus musculus (182)
Mycobacterium tuberculosis SP7 (43)
Mycobacterium tuberculosis SP10 (43)
Mycobacterium tuberculosis SP13 (43)
Mycobacterium tuberculosis SP22 (43)
Chlamydomonas reinhardtii (43)
Enterococcus mundtii CRL35 (43)
Oncorhynchus tshawytscha (43)
Pseudomonas canadensis (43)
Pseudomonas aeruginosa PAO1H2O (43)
Human alphaherpesvirus 1 strain 17 (43)
Saccharomyces cerevisiae (19)
Rattus norvegicus (8)
Drosophila melanogaster (7)
Caenorhabditis elegans (6)
Schizosaccharomyces pombe (3)
human gammaherpesvirus 4 (3)
Vertebrata (2)
Klebsiella pneumoniae subsp. pneumoniae MGH 78578 (2)
Bacillus methanolicus (1)
Candidatus Pelagibacter ubique HTCC1062 (1)
Bacillus subtilis (1)
Hordeum vulgare (1)
Plasmodium falciparum (1)
Pseudomonas aeruginosa (1)
Sus scrofa (1)
Mangifera indica (1)
Human gammaherpesvirus 8 (1)
Malus domestica (1)

Organisms

Homo sapiens (195)
Mus musculus (98)
Saccharomyces cerevisiae (10)
Rattus norvegicus (3)
Papaver somniferum (1)
Mangifera indica (1)
Schizosaccharomyces pombe (1)
Malus domestica (1)

Repository

ENA (342)
geo (309)
biostudies-arrayexpress (208)
pride (43)
MassIVE (14)
iProX (4)
jPOST (4)
MetaboLights (4)
BioModels (2)
Cell Collective (2)
PAXDB (1)

Tissue

Cell culture (13)
Brain (6)
Spleen (4)
HEK-293T cell (2)
Embryonic stem cell (2)
Myeloid cell (2)
Permanent cell line cell (2)
Epithelial cell (2)
TEX cell (1)
MOLM-14 cell (1)
MV-4-11 cell (1)
MOLM-16 cell (1)
Cervical cancer cell line (1)
Spermatid (1)
Cerebellar neuron (1)
Epithelial cell of lung (1)
Spinal cord (1)
Dendritic cell (1)
Testis (1)
Lung (1)
Embryonic kidney cell line (1)
Liver (1)
T cell (1)
Blood (1)

Disease

Hepatomegaly (1)
Carcinoma (1)
Colorectal Neoplasms (1)
Substance abuse (1)
Allergy (1)
Pollen allergy (1)
Multiple sclerosis (1)
Brain glioblastoma multiforme (1)
Systemic lupus erythematosus (1)
Renal clear cell carcinoma (1)
Melanoma (1)
Pancreatic cancer (1)
Schizophrenia (1)
Ulcerative colitis (1)
Kidney cancer (1)
Acute leukemia (1)

Technology Type

Mass Spectrometry (43)
Shotgun proteomics (20)
Bottom-up proteomics (11)
Affinity purification coupled with mass spectrometry proteomics (5)
Data-dependent acquisition (4)
SWATH MS (3)
Mass spectrometry assay (2)
Data-independent acquisition (2)
NMR spectroscopy (1)
Mass spectrometry (1)
Gel-based experiment (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)

Instrument Platform

NextSeq 500 (5)
TripleTOF 5600 (5)
Q Exactive (4)
NextSeq 550 (3)
Illumina NovaSeq 6000 (3)
Illumina HiSeq 4000 (3)
MinION (2)
Illumina HiSeq 2500 (2)
Q Exactive Plus (2)
Gene Titan (1)
Sony SH800S (1)
DNBSEQ-G400 (1)
LTQ Orbitrap Elite (1)
LTQ Orbitrap XL (1)
Q Exactive HF (1)
Orbitrap Fusion Lumos (1)
Nuclear Magnetic Resonance (NMR) - (1)
Liquid Chromatography MS - alternating - reverse-phase (1)
Liquid Chromatography MS - alternating - hilic (1)
Liquid Chromatography MS - negative - hilic (1)
Liquid Chromatography MS - positive - hilic (1)
Liquid Chromatography MS - positive - reverse phase (1)
Liquid Chromatography MS - negative - reverse phase (1)

Publication Date

2013 (59)
2020 (54)
2016 (51)
2026 (42)
2015 (41)
2022 (36)
2014 (35)
2017 (35)
2024 (31)
2021 (31)
2018 (31)
2023 (28)
2025 (24)
2012 (23)
2010 (20)
2019 (19)
2011 (8)
2008 (6)
2007 (5)
2009 (4)
2006 (3)

UNIPROT ID/AC

ORC6_YEAST (1)
NAP1_YEAST (1)
GGC1_YEAST (1)
MCFS1_YEAST (1)
MSH4_YEAST (1)
ARI1_YEAST (1)
RMT2_YEAST (1)
YNR4_YEAST (1)
HCH1_YEAST (1)
NTM1_YEAST (1)
SECU_YEAST (1)
LDB16_YEAST (1)
NSG1_YEAST (1)
EAF3_YEAST (1)
IRC8_YEAST (1)
REV7_YEAST (1)
H3_YEAST (1)
MMS1_YEAST (1)
OYE2_YEAST (1)
RRN10_YEAST (1)
ACON_YEAST (1)
SRL3_YEAST (1)
RNP1_YEAST (1)
TPS2_YEAST (1)
YO131_YEAST (1)
REB1_YEAST (1)
NAA25_YEAST (1)
STD1_YEAST (1)
LIF1_YEAST (1)
YOL18_YEAST (1)

CHEBI ID

CHEBI:85363 (1)
CHEBI:27856 (1)
CHEBI:89843 (1)
CHEBI:70959 (1)
CHEBI:17634 (1)
CHEBI:48430 (1)
CHEBI:36313 (1)
CHEBI:30751 (1)
CHEBI:17790 (1)
CHEBI:18295 (1)
CHEBI:15347 (1)
CHEBI:16236 (1)
CHEBI:17824 (1)
CHEBI:29864 (1)
CHEBI:16283 (1)
CHEBI:16977 (1)
CHEBI:15428 (1)
CHEBI:15741 (1)
CHEBI:17268 (1)
CHEBI:9349 (1)
CHEBI:7563 (1)
CHEBI:16335 (1)
CHEBI:17568 (1)
CHEBI:15355 (1)
CHEBI:7916 (1)
CHEBI:17750 (1)
CHEBI:16467 (1)
CHEBI:18019 (1)
CHEBI:18183 (1)
CHEBI:35932 (1)

Metabolite Name

Glycine (4)
L-Cystine (3)
Ketoleucine (3)
Xanthurenic acid (3)
Rosmic acid (2)
1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine (2)
1-Stearoyl-2-linoleoyl-sn-glycero-3-phosphocholine (2)
Thelephoric acid (2)
Ezetimibe (2)
DHBOA-Glc (2)
Oleuropein (2)
Rutarin (2)
Emtricitabine (2)
Hypericin (2)
Ginkgolide C (2)
Cassiaside C (2)
Oleoside 11-methyl ester (2)
P-Toluenesulfonic acid (2)
Etoposide (2)
Chlorogenic acid (2)
Dihydrofolic acid (2)
Valylphenylalanine (2)
Doxycycline (2)
Arbutin (2)
Prenyl glucoside (2)
Nitecapone (2)
S-Adenosylmethionine (2)
Cefuroxime (2)
Isoxanthopterin (2)
Anserine (2)

First Public Date

2020 (45)
2017 (30)
2026 (29)
2022 (29)
2021 (28)
2023 (27)
2018 (27)
2024 (25)
2025 (22)
2019 (21)
2014 (21)
2016 (18)
2015 (11)
2013 (9)

Modelling Approach

Logical model (2)

Study status

Not yet recruiting (1)
Recruiting (1)

Lab affiliation

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02215, USA (3)
Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (3)
The Drug Discovery Lab, Mary S. Easton Center for Alzheimer’s Disease Research, Department of Neurology, David Geffen School of Medicine, 710 Westwood Plaza, University of California Los Angeles, Los Angeles, CA 90095, USA (2)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (2)
Dept. of Molecular Biosciences, University of Texas at Austin, Texas 78712 USA (2)
Systems Biology Ireland, University College Dublin (2)
Department of Cellular Biology and Immunology, Lab 201, IPBLN-CSIC, Granada, Spain. (1)
Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research and Jewish General Hospital, and McGill University, Montréal, Québec, Canada Gerald Bronfman Department of Oncology, McGill University, Montréal, Québec, Canada (1)
EDyP team (1)
BRIC-National Centre for Cell Science, Pune (1)
Director, Proteomics and Metabolomics Facility, Center for Open Research Resources and Equipment, University of Connecticut, Storrs, CT, USA (1)
The Institute of Cancer research (1)
Maj Institute of Pharmacology, Polish Academy of Sciences, Department of Pharmacology, Laboratory of Pharmacology and Brain Biostructure, Smetna Str. 12, 31-343 Krakow, Poland (1)
School of Life Science, Peking University (1)
Laboratory of Cancer Metabolism, Department of Experimental Oncology, Maria Sklodowska-Curie National Research Institute of Oncology (1)
- Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil (1)
1 Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, PR China 2 Department of Microbiology and Immunology, Tongji University School of Medicine, Shanghai 200049, PR China 3 Clinical Translation Research Center, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China. (1)
Shanghai university of Traditional Chinese Medicine (1)
University Medical Center, Department of Clinical Chemistry, Core Facility Proteomics (1)
Dana-Farber Cancer Institute 450 Brookline Avenue, Longwood Center 3217 Boston, MA 02215 (1)
Department of Biochemistry, Vanderbilt University, USA (1)
New York University (1)
Interfaculty Institute of Biochemistry, University of Tübingen, Tübingen, Germany (1)
Biozentrum, University of Basel, Basel, Switzerland (1)
University of Salzburg, Department of Molecular Biology, Division of Chemistry and Bioanalytics, Hellbrunnerstraße 34, 5020 Salzburg, Austria (1)
Medicinal Chemistry, Monash Institute of Pharmaceutica Science, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia (1)
Georgetown University, USA (1)
St.jude children's research hospital (1)
Department of Life Technologies and InFLAMES Research Flagship, University of Turku, FI-20014, Turku, Finland (1)
Raymond H. Wittcoff Distinguished Professor and Head Department of Biochemistry and Molecular Biophysics Washington University School of Medicine St. Louis, MO 63110 (1)

Keyword

Antineoplastic Agents, Immunological (1)
Antibodies (1)
Immunoglobulins (1)
Antibodies, Monoclonal (1)
Capecitabine (1)
Cetuximab (1)

IsPrivate

False (2)

Modification

Not available (1)

Study type

Transcription profiling by array (75)
ChIP-seq (44)
ChIP-chip by tiling array (34)
RNA-seq of coding RNA (33)
Comparative genomic hybridization by array (5)
Unknown experiment type (4)
Transcription profiling by tiling array (3)
RNA-seq of coding RNA from single cells (3)
Other (2)
Interventional (2)
Animal - High-throughput sequencing (1)
Cell line - High-throughput sequencing (1)
DNA-seq (1)
Methylation profiling by high throughput sequencing (1)
RNA-seq of total RNA (1)

Release Date

2022 (103)
2021 (93)
2016 (80)
2020 (75)
2015 (75)
2013 (75)
2014 (71)
2017 (71)
2023 (70)
2019 (67)
2018 (64)
2024 (50)
2025 (39)
2012 (36)
2010 (33)
2011 (18)
2009 (12)
2026 (11)
2008 (11)
2007 (11)
2006 (4)
2005 (3)
2003 (2)
2000 (2)
2002 (1)
1998 (1)

Location

United States (1)

Previous page
1 / 181
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 181
Next page

Sort by:

Relevance

Page size

Streptococcus anginosus promotes hepatocellular carcinoma progression and BET inhibitor resistance by inducing BRD4 lactylation

Hepatocellular carcinoma (HCC) is a highly aggressive form of carcinoma with a poor prognosis. Diagnostic markers and potential therapeutic targets for HCC are urgently needed. Here, we demonstrate that fecal microbiota transplantation (FMT) using stool samples from HCC patients significantly pro...

2025-12-05 | MTBLS12398 | MetaboLights

Functions of BET proteins in GATA1-mediated transcription [expression array]

Role of bromodomain and extra-terminal motif (BET) proteins in GATA1-null erythrolbasts (G1E) and in differentiation induced by activation of conditional GATA1 tested by addition of BET inhibitor JQ1 (250nM) Array protocols were conducted as described in the Ambion WT Expression Manual and the Affym...

ORGANISM(S): Mus musculus

2015-02-23 | E-GEOD-62709 | biostudies-arrayexpress

Functions of BET proteins in GATA1-mediated transcription [ChIP-seq]

Transcription factor GATA1 binding in erythroblasts in the presence and absence of BET inhibitor JQ1, and BET protein BRD3 and BRD4 binding in erythroblasts in the presence and absence of GATA1. Inhibitors of Bromodomain and Extra-Terminal motif proteins (BETs) are being evaluated for the treatment...

ORGANISM(S): Mus musculus

2015-02-23 | E-GEOD-62736 | biostudies-arrayexpress

ChIP of BET proteins in iBET resistance [ChIP-seq]

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers1,2. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluati...

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63682 | biostudies-arrayexpress

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (ChIP-Seq)

Men who develop metastatic castration-resistant prostate cancer (CRPC) invariably succumb to the disease. The development and progression to CRPC following androgen ablation therapy is predominantly driven by unregulated androgen receptor (AR) signaling1-3. Despite the success of recently approved...

ORGANISM(S): Homo sapiens

2014-04-25 | E-GEOD-55062 | biostudies-arrayexpress

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

We analyzed transcriptional changes in 4 prostate cancer cell lines following treatment with the BET inhibitor I-BET762 using Affymetrix Human Genome U133 Plus 2.0 Arrays. Four prostate cancer cell lines (NCI-H660, VCaP, LNCaP, PC-3) were treated with DMSO (control) or I-BET762 at 0.5uM or 10uM con...

ORGANISM(S): Homo sapiens

2014-03-31 | E-GEOD-56352 | biostudies-arrayexpress

Genome wide expression analysis of BET inhibitor resistance

Bromodomain and Extra Terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic paradigm by directly targeting epigenetic readers. Early clinical trials have shown significant promise especially in acute myeloid leukaemia (AML)3; therefore the evaluation ...

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63575 | biostudies-arrayexpress

Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (microarray)

ORGANISM(S): Homo sapiens

2014-04-25 | E-GEOD-55063 | biostudies-arrayexpress

Genome wide expression analysis of BET inhibitor resistance [RNA-seq]

ORGANISM(S): Mus musculus

2015-09-15 | E-GEOD-63681 | biostudies-arrayexpress

BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure [ChIP-Seq]

Heart failure is driven by the interplay between master regulatory transcription factors and dynamic alterations in chromatin structure. Coordinate activation of developmental, inflammatory, fibrotic and growth regulators underlies the hallmark phenotypes of pathologic cardiac hypertrophy and contra...

ORGANISM(S): Mus musculus

2013-08-06 | E-GEOD-46668 | biostudies-arrayexpress

Previous page
1 / 181
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 181
Next page

Sort by:

Relevance

Page size

1806 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

UNIPROT ID/AC

CHEBI ID

Metabolite Name

First Public Date

Modelling Approach

Study status

Lab affiliation

Tags

Keyword

IsPrivate

Modification

Study type

Release Date

Location

OmicsDI is part of the ELIXIR infrastructure

Tweets